June 19 The number of drugs dispensed to U.S.
minors has dropped slightly over the past decade, bucking the
rise in prescriptions to adults, with a drop in the use of
antibiotics standing out, according to a government report.
But use of other drugs rose, with stimulants used to treat
attention deficit hyperactivity disorder (ADHD) leading the
pack, said the report, published in the journal Pediatrics.
From 2002 to 2010, the use of ADHD drugs grew by 46 percent,
or some 800,000 prescriptions a year, wrote researchers from the
U.S. Food and Drug Administration.
The top drug dispensed to adolescents was the stimulant
methylphenidate, also known as Ritalin, with more than four
million prescriptions filled in 2010.
"What the article is suggesting is that the number of
children that we are treating for attention deficit disorder has
gone up," said Scott Benson, a child and adolescent psychiatrist
and a spokesperson for the American Psychiatric Association.
"For the most part I think the overall increase reflects a
reduction in the stigma. It used to be 'You're a bad parent if
you can't get your child to behave, and you're a doubly bad
parent if you put them on medicine."
Antibiotic use fell by 14 percent, suggesting that efforts
to curb rampant overuse of the drugs "may be working," the
Experts say antibiotics are commonly used to treat
infections caused by viruses, although they only work against
bacteria - and that has fueled the growth of drug-resistant
The findings were based on data from healthcare research
firm IMS Health and do not include drugs given at hospitals.
Overall, there were 263 million filled prescriptions to
minors in 2010, down seven percent since 2002. After taking
population changes into account, that corresponds to a
By contrast, adult prescriptions rose by 11 percent.
Prescription drug classes that showed marked dips among
children included allergy medicines, cough and cold drugs,
painkillers and antidepressants.
Apart from ADHD drugs, asthma medicine and birth control
pills also showed increases.
The FDA said it could not explain the reasons behind the
(Reporting from New York by Frederik Joelving at Reuters
Health; editing by Elaine Lies)